OrthoPediatrics Corp Completes Acquisition of Brazilian Distributor Folomed

Why It Matters

Turning to positive cash flow and accelerating margin expansion demonstrates a sustainable growth trajectory, strengthening OrthoPediatrics' appeal to investors and cementing its leadership in pediatric orthopedics.

Key Takeaways

• Q1 revenue $61.6M, up 17% YoY.
• Gross margin rose to 73% from 68%.
• First positive free cash flow quarter, $10M.
• International revenue up 33%, driven by LatAm, EMEA, APAC.
• New product launches and EU MDR approvals expand growth pipeline.

Pulse Analysis

The pediatric orthopedics market is expanding as hospitals and surgeons seek devices tailored to children’s unique anatomy and growth patterns. OrthoPediatrics, the sector’s clear market leader, benefits from a differentiated portfolio that spans trauma, deformity, scoliosis and specialty bracing. Its focus on innovation—evidenced by recent launches such as the 3P Hip, Vertaglyde and the upcoming ELLI electromechanical spine system—aligns with a broader industry shift toward growth‑friendly, minimally invasive solutions, positioning the company to capture a larger share of a market projected to grow at double‑digit rates.

Financially, the quarter’s 17% revenue growth and a 73% gross margin underscore the effectiveness of OrthoPediatrics’ product‑mix strategy. Adjusted EBITDA surged 59% while operating expenses rose only 7%, reflecting disciplined cost management. The historic $10 million positive free cash flow marks a turning point, reducing reliance on external financing and providing flexibility for further R&D investment. By reaffirming 2026 guidance of $262‑$266 million revenue and $25 million adjusted EBITDA, management signals confidence in sustaining momentum despite macro‑economic headwinds.

Strategic initiatives further amplify growth prospects. The acquisition of Folomed streamlines cash collection and ordering in Brazil, a key Latin American market, while EU MDR approvals unlock the full product suite for European surgeons, likely boosting international sales. Coupled with a robust pipeline—including the first‑in‑human ELLI implant slated for late‑2026 and a digital surgical platform, Playbook—OrthoPediatrics is building a comprehensive ecosystem that extends beyond implants to data‑driven care. These moves reinforce the company’s competitive moat and suggest a durable, multi‑year growth trajectory for shareholders.

Deal Summary

OrthoPediatrics Corp announced the acquisition of Folomed, a Brazilian distributor, to improve cash collection and ordering patterns in Latin America. The deal, disclosed during the company's Q1 2026 earnings call, aims to strengthen OrthoPediatrics' international footprint and accelerate growth in Brazil. Deal value was not disclosed.